Abstract:

Objective This retrospective study was aimed to compare the efficacy and safety of dapa⁃ gliflozin combined with metformin and sitagliptin combined with metformin in the treatment of overweight and obese type 2 diabetes. Methods A total of 217 patients with type 2 diabetes in whom the body mass index （BMI）> 25 kg/m2 were divided into dapagliflozin group（n = 107）and sitagliptin group（n = 110）according to different treatment options. After 24 ⁃ week treatment，fasting blood glucose （FBG），glycosylated hemoglobin （HbA1c）and other related metabolic indicators before and after treatment were compared. The adverse reactions during medication were recorded. Results After 24 ⁃ week treatment，FBG，HbA1c，blood lipid and uric acid were decreased in both groups（P < 0.05），but there was no statistical difference between the two groups（P > 0.05）. Body weight，waist circumference，systolic and diastolic blood pressure were decreased in the dapagliflozin group （P < 0.05）. Urogenital tract infection was increased in the dapagliflozin group，and diabetic ketoacidosis with normal blood sugar occurred，with more adverse reactions than that in the sitagliptin group，showing statistical difference（P < 0.05）. Conclusion Dapagliflozin combined with metformin and sitagliptin combined with metformin had the same hypoglycemic effect on overweight and obese patients with type 2 diabetes. Dapagliflozin could effectively reduce the body weight，waist circumference and blood pressure，but its risk of urogenital tract infection and diabetic ketoacidosis should be noticed. In terms of safety，Sitagliptin is much better than Dapagliflozin.

Key words: dapagliflozin,  , sitagliptin,  , type 2 diabetes mellitus,  , metformin,  , obesity